cardiac cta image

COVID-19 Treatment Information

Registration for COVID-19 monoclonal antibody treatment is not available in Broward Health’s emergency rooms and is by appointment only. To schedule an appointment for monoclonal antibody treatment for COVID-19, you must:

  1. Have a referral from a primary care physician
  2. Have a positive COVID-19 PCR or Rapid Test result
  3. Meet Centers for Disease Control and Prevention criteria.

To verify if you are eligible, call Broward Health’s free, Nurse Connect line 7 days a week from 7am - 10pm to speak with a registered nurse: 954-320-5730.

Additional information on COVID-19 treatment and how to get it is available on the Florida Department of Health COVID-19 response page. If you are experiencing a medical emergency, call 9-1-1 or visit the emergency room.

For Patients: 

To more effectively treat emerging variants of COVID-19, and in accordance with recent FDA guidelines, Broward Health has updated its monoclonal antibody therapy.

The FDA has issued an Emergency Use Authorization (EUA) to permit the use of bebtelovimab. Effective immediately, Broward Health will no longer administer sotrovimab and will replace the therapy with Bebtelovimab.

Increased resistance against sotrovimab from the Omicron BA.2 variant has been cited by the FDA. Bebtelovimab has shown promising results at treating this variant, and the FDA recommends this therapy as an alternative to sotrovimab. Broward Health has received a limited supply and will be prioritizing treatment to those patients who are COVID-19 positive and are most at-risk for hospitalization and death (e.g., transplant recipients, oncology patients, pregnant patients, etc.).

Please review the EUA fact sheet for more information on the treatment and consult with your healthcare provider to determine if you are a candidate. This treatment is most effective when given immediately following COVID-19 diagnosis. This information is provided as a community education resource.

COVID clinical trials

For Providers: 

The FDA has issued an Emergency Use Authorization (EUA) to permit the use of bebtelovimab. Effective immediately, Broward Health will no longer administer sotrovimab and will replace the therapy with bebtelovimab.

Increased resistance against sotrovimab from the Omicron BA.2 variant has been cited by the FDA. Bebtelovimab has shown promising results at treating this variant, and the FDA recommends this therapy as an alternative to sotrovimab. Broward Health has received a limited supply and will be prioritizing treatment to those patients who are COVID-19 positive and are most at-risk for hospitalization and death (e.g., transplant recipients, oncology patients, pregnant patients, etc.).

All inclusion and exclusion criteria will remain the same as indicated on the sotrovimab therapy order form. Bebtelovimab can be used for the treatment of mild to moderate COVID-19 in adult and pediatric patients who are 12 years of age and older weighing at least 40 kg, with a positive result of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19 and/or hospitalization. Monoclonal antibody therapy is only indicated in the outpatient setting.

 

Please review the EUA, order form, and letter to ordering physicians and APRNs who are not credentialed at Broward Health.